Curative carbon ion radiotherapy in a head and neck mucosal melanoma series: Facing the future within multidisciplinarity

Sara Ronchi(National Center for Oncological Hadrontherapy), Barbara Vischioni(National Center for Oncological Hadrontherapy), Piero Nicolai(University of Padua), Paolo Castelnuovo(University of Insubria), A. Cicchetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Rossana Ingargiola(National Center for Oncological Hadrontherapy), Ernesto Pasquini(Azienda USL di Bologna), Mohssen Ansarin(European Institute of Oncology), Marco Benazzo(University of Pavia), Stefania Russo(National Center for Oncological Hadrontherapy), Anna Maria Camarda(National Center for Oncological Hadrontherapy), Sara Imparato(National Center for Oncological Hadrontherapy), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Ester Orlandi(Fondazione IRCCS Istituto Nazionale dei Tumori), Maria Bonora(National Center for Oncological Hadrontherapy)
Radiotherapy and Oncology
November 11, 2023
10.1016/j.radonc.2023.110003
Cited by 13

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Interleukin-12: Biological Properties and Clinical Application
|Clinical Cancer Research|2007|606
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2020|530
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
|The Lancet Oncology|2017|501